Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Christopher Rhodes

Will head cardiovascular and metabolic diseaseresearch for the AZ unit

AstraZeneca MedImmune Dr Christopher RhodesAstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research.

Dr Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, as well as contributing to the unit's product development goals.

He joins MedImmune from the University of Chicago, where he held a research director's role that covered diabetes, endocrinology and molecular metabolism and nutrition.

In that position he led a large team of researchers focused on molecular mechanisms that control key functions in the pathogenesis of diabetes and obesity.

YongJun Liu, senior vice president of R&D at MedImmune, said: “I am delighted to welcome Dr Rhodes, a world-renowned researcher in the diabetes field, to MedImmune at this extremely exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

“With his wealth of experience, we know he will propel MedImmune to the next level in metabolic disease, guiding our overall CVMD research strategy and driving results to ensure a seamless process for the progression of new drug candidates through the development process, with the ultimate goal of delivering novel medicines to patients.”

10th August 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics